[go: up one dir, main page]

PA8436501A1 - Ligandos espirociclicos de un subtipo de receptor de la dopamina. - Google Patents

Ligandos espirociclicos de un subtipo de receptor de la dopamina.

Info

Publication number
PA8436501A1
PA8436501A1 PA19978436501A PA8436501A PA8436501A1 PA 8436501 A1 PA8436501 A1 PA 8436501A1 PA 19978436501 A PA19978436501 A PA 19978436501A PA 8436501 A PA8436501 A PA 8436501A PA 8436501 A1 PA8436501 A1 PA 8436501A1
Authority
PA
Panama
Prior art keywords
spyrocyclic
leagues
dopamine receptor
receptor subtype
useful
Prior art date
Application number
PA19978436501A
Other languages
English (en)
Inventor
Todd Williams Butler
Anton Franz Joseph Fliri
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8436501A1 publication Critical patent/PA8436501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS COMPUESTOS FARMACEUTICAMENTE ACTIVOS DE FORMULA 1 EN LA QUE A, B Y R1 A R6 SON COMO SE HAN DEFINIDO EN LA MEMORIA. ESTOS COMPUESTOS PRESENTAN ACTIVIDAD DOPAMINERGICA CENTRAL Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL.
PA19978436501A 1996-08-26 1997-08-22 Ligandos espirociclicos de un subtipo de receptor de la dopamina. PA8436501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2479796P 1996-08-26 1996-08-26

Publications (1)

Publication Number Publication Date
PA8436501A1 true PA8436501A1 (es) 2000-05-24

Family

ID=21822443

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978436501A PA8436501A1 (es) 1996-08-26 1997-08-22 Ligandos espirociclicos de un subtipo de receptor de la dopamina.

Country Status (22)

Country Link
US (1) US6664258B1 (es)
EP (1) EP0925291B1 (es)
JP (1) JP3152941B2 (es)
AP (1) AP9701075A0 (es)
AR (1) AR013836A1 (es)
AT (1) ATE311377T1 (es)
AU (1) AU3632297A (es)
CA (1) CA2264549C (es)
CO (1) CO4560554A1 (es)
DE (1) DE69734774D1 (es)
GT (1) GT199700096A (es)
HN (1) HN1997000117A (es)
HR (1) HRP970455A2 (es)
ID (1) ID18076A (es)
IL (1) IL128050A0 (es)
IS (1) IS4969A (es)
MA (1) MA26437A1 (es)
PA (1) PA8436501A1 (es)
PE (1) PE108498A1 (es)
TN (1) TNSN97143A1 (es)
WO (1) WO1998008835A1 (es)
ZA (1) ZA977597B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
GB0328906D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758919A (fr) 1969-11-15 1971-05-13 Merck Patent Gmbh Spiro-composes
US4025558A (en) 1974-04-12 1977-05-24 The Upjohn Company Organic compounds
US3932425A (en) 1974-04-12 1976-01-13 The Upjohn Company Benzospiran derivatives
US4010201A (en) 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
DE2818329A1 (de) 1978-04-26 1979-11-08 Yoshitomi Pharmaceutical Spiro eckige klammer auf cyclohexan- 1,9'-thioxanthen eckige klammer zu -verbindungen
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
ATE182139T1 (de) 1992-10-23 1999-07-15 Merck Sharp & Dohme Dopamin rezeptor subtyp liganden
GB9317631D0 (en) 1993-08-25 1993-10-13 Bxl Plastics Ltd Multi-layered composite
US5403846A (en) 1993-11-22 1995-04-04 Merck & Co., Inc. Spirocycles
AU691296B2 (en) * 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
GB9410031D0 (en) 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
IS4969A (is) 1999-02-05
JP2000502360A (ja) 2000-02-29
JP3152941B2 (ja) 2001-04-03
PE108498A1 (es) 1999-01-29
ZA977597B (en) 1999-02-25
HN1997000117A (es) 1997-12-26
WO1998008835A1 (en) 1998-03-05
CO4560554A1 (es) 1998-02-10
AP9701075A0 (en) 1997-10-31
CA2264549C (en) 2004-09-14
ID18076A (id) 1998-02-26
MA26437A1 (fr) 2004-12-20
IL128050A0 (en) 1999-11-30
EP0925291A1 (en) 1999-06-30
AU3632297A (en) 1998-03-19
TNSN97143A1 (fr) 2005-03-15
AR013836A1 (es) 2001-01-31
HRP970455A2 (en) 1998-08-31
DE69734774D1 (de) 2006-01-05
GT199700096A (es) 1999-02-16
EP0925291B1 (en) 2005-11-30
CA2264549A1 (en) 1998-03-05
ATE311377T1 (de) 2005-12-15
US6664258B1 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
MX9606450A (es) Derivados de bencimidazolona.
PA8436501A1 (es) Ligandos espirociclicos de un subtipo de receptor de la dopamina.
PA8521501A1 (es) Ligandos para receptores de melanocortina
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
CU23167A3 (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
MX9301634A (es) Quinuclidinas peptidicas.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
AR039489A1 (es) Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PE20020505A1 (es) Grupos quinuclidina sustituidos con heteroarilo para el tratamiento de enfermedades
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
ATE247639T1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
ES2184106T3 (es) Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
AR028705A1 (es) Bis-arilsulfonas
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
DE60003899D1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
ES2132401T3 (es) Tetrahidro-1h-benzazepinonas y hexahidroazepinonas como antagonistas selectivos del receptor colecistoquinina-b.